Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia missed their primary endpoints. AbbVie’s two ...
Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia ...
Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in ...
AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical company's shares ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...
AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% in ...
Price Action: AbbVie stock is down 10.6% at $178.32, while Bristol Myers Squibb stock is up 13% at $61.20 during the ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
The rapidly growing aging population is driving expansion in healthcare, with rising demand for treatments and chronic disease management. Companies like AbbVie (ABBV), Medtronic (MDT), and Centene ...
Option chain shows key data for AbbVie's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AbbVie.
On Tuesday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $201.68 which represents a slight increase of $1.21 or 0.60% from the prior close of $200.47. The stock opened at $200.49 and ...
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback